用重组干扰素α（rIFNα）或甲磺酸伊马替尼治疗真性红细胞增多症。
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.
作者信息
Silver Richard T
机构信息
New York Presbyterian-Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA.
出版信息
Curr Hematol Rep. 2005 May;4(3):235-7.
PMID:15865878
Abstract
Polycythemia vera (PV) is a myeloproliferative disease which if untreated leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis of the marrow, anemia, and splenomegaly. Two new drugs are now available, interferon and imatinib mesylate, which may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of the cases.
摘要
真性红细胞增多症（PV）是一种骨髓增殖性疾病，若不治疗会导致血栓出血并发症，并最终发展为骨髓进行性骨髓纤维化、贫血和脾肿大。目前有两种新药可供使用，即干扰素和甲磺酸伊马替尼，它们可能会改变这种疾病的病程。作为单一药物使用时，每种药物在约75%的病例中都能产生持久缓解。
Zotero 插件